title: [Surgical treatment for patients with advanced gastrointestinal stromal tumor after targeted therapy].
abstract: OBJECTIVE
  To explore the role of surgery and its long-term outcome in patients with advanced gastrointestinal stromal tumor(GIST) treated with imatinib preoperatively.
  
  
  METHODS
  Thirteen patients receiving imatinib therapy preoperatively, were retrospectively assessed for completeness of surgical resection and for disease-free and overall survival after resection.
  
  
  RESULTS
  Thirteen patients, including 3 patients with locally advanced primary GIST and 10 patients with recurrent or metastatic GIST, underwent surgery after preoperative treatment with imatinib. Complete resections were accomplished in 4 of the 5 responsive disease(RD) patients, and in 1 of the 8 progression disease(PD) patients (38.5%). The progression-free survival(PFS) time for patients with RD and PD were 24.8 months and 2.8 months respectively. The difference of PFS between patients with RD and those with PD was significant(P<0.01). Median overall survival(OS) was not reached in both patients with RD and PD. The difference of OS between patients with RD and those with PD was not significant(P>0.05).
  
  
  CONCLUSIONS
  Surgical intervention following imatinib is feasible and can be considered for patients with advanced GIST responsive to imatinib.
authors.affiliation: Abdominal Cancer Institute, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
authors.forename: Chun-meng
authors.initials: CM
authors.lastname: Wang
authors.forename: Ying-qiang
authors.initials: YQ
authors.lastname: Shi
authors.forename: Yan-wei
authors.initials: YW
authors.lastname: Ye
authors.forename: Hong
authors.initials: H
authors.lastname: Fu
authors.forename: Guang-fa
authors.initials: GF
authors.lastname: Zhao
authors.forename: Ye
authors.initials: Y
authors.lastname: Zhou
authors.forename: Chun-yan
authors.initials: CY
authors.lastname: DU
authors.forename: Rui-zeng
authors.initials: RZ
authors.lastname: Dong
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides; D018572:Disease-Free Survival; D005260:Female; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000601:surgery*; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage*; D011379:Prognosis; D011743:Pyrimidines / Q000008:administration & dosage*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate